Azmi & Associates is proud to announce its role in advising the National Institutes of Biotechnology Malaysia (NIBM), under the Ministry of Science, Technology, and Innovation (MOSTI), on the signing of a Memorandum of Agreement (MoA) with CanSino Biologics Inc., a leading biopharmaceutical company from China.
The MoA, signed by YBhg. Prof. Datuk Wira Dr. Raha Abdul Rahim, CEO of NIBM, and Mr. Wang Hong Yi, representing CanSino Biologics Inc., marks a significant milestone in the bilateral cooperation between Malaysia and China. The signing ceremony was graced by the presence of YB Tuan Chang Lih Kang, Minister of Science, Technology, and Innovation, Malaysia, and Mr. Chen Youliang, Minister Counsellor of the Embassy of the People’s Republic of China to Malaysia.
Azmi & Associates provided comprehensive legal advisory services, ensuring the agreement aligns with the strategic goals of both parties. This MoA aims to enhance joint research initiatives in the development of human vaccine platforms, researcher exchanges, technology transfers, biomanufacturing, and laboratory testing.
Our Multimedia, Technology & Intellectual Property (MTIP) Practice Group, led by Khairul Fazli Abdul Kadir (Partner) and supported by Khaliesah Yusri Kamaruzaman (Associate), played a crucial role in this assignment by drafting, negotiating, and finalising the MoA.
The joint research and development project, which includes talent and expert exchange as well as technology transfer, is set to be completed within two years. This initiative is expected to significantly contribute to Malaysia’s aspirations of becoming self-sufficient in vaccine production by 2030.
Azmi & Associates is honoured to have facilitated this landmark agreement, which will play a crucial role in advancing Malaysia’s biotechnology and vaccine manufacturing capabilities. We look forward to continuing our support for initiatives that drive innovation and international collaboration.
Read More: https://www.facebook.com/share/p/g2yXwtbHBW5L5DBP/
Corporate Communications
Azmi & Associates
25 July 2024
